Your Article(s)
There are no articles yet
Cart 0
0
-
- Shop
- Show All Products
- Akt Signalling
- Alzheimer
- Autophagy
- beta-Catenin
- Blocking Peptides
- Buffers and Reagents
- Cell lysates
- COVID-19
- EGF Receptor erbB
- EGFR Downstream Signaling
- MAP kinases SAP kinases
- Miscellaneous antibodies
- Phosphospecific antibodies
- PKG-PKA-Signalling
- Receptor Tyrosine kinases
- Serine- Threonine kinases
- Transcription-factors
- Tyrosine kinases
- About Us
- Custom Monoclonal Antibodies
- Antibody Libraries
- Contact
- Login/Register
SHOP: EGF Receptor erbB,Blocking Peptides
Back to ListBlocking Peptide phospho-EGFR, pTyr 1045
| Order No. | Size sufficient for | Price | |
|---|---|---|---|
| 2004-100/EGFR-pTyr1045 | 208,00 € | ||
| Order No.: | 2004-100/EGFR-pTyr1045 |
| Description: | |
| Specificity: | Blocking Peptide for monoclonal antibody EGFR-11C2 |
| Size sufficient for: | |
| Formulation: | lyophilized |
| Applications: | Blocking of mab EGFR-11C2 (pTyr 1045) |
| Price: | 208,00 € |
| References: | Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Hudelist G, K�stler J, Czerwenka K, Kubista E, Attems J, M�ller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hosch�tzky H, Zielinski CC, Singer CF. Int. J. Cancer: 118, 1126-1134 (2006) |